Plasma concentrations and receptor binding of RU 486 and its metabolites in humans.
about
The Treatment of Cushing's Disease.Role of "old" pharmacological agents in the treatment of Cushing's syndromeEffects of selective and non-selective glucocorticoid receptor II antagonists on rapid-onset diabetes in young ratsThe Concise Guide to PHARMACOLOGY 2013/14: nuclear hormone receptors.Time-dependent corticosteroid modulation of prefrontal working memory processingSimultaneous determination of mifepristone and monodemethyl-mifepristone in human plasma by liquid chromatography-tandem mass spectrometry method using levonorgestrel as an internal standard: application to a pharmacokinetic study.Selective serotonin reuptake inhibitor and substance P antagonist enhancement of natural killer cell innate immunity in human immunodeficiency virus/acquired immunodeficiency syndromeMolecular determinants of glucocorticoid receptor mobility in living cells: the importance of ligand affinityChanges in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone.Human glucocorticoid receptor beta binds RU-486 and is transcriptionally active.Glucocorticoid receptor-mediated transcriptional regulation of N-acetyltransferase 1 gene through distal promoterThe potential of mifepristone (RU-486) as an emergency contraceptive drug.Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology.Mifepristone Accelerates HPA Axis Recovery in Secondary Adrenal InsufficiencySynthesis, spectral characterization, and in vitro cellular activities of metapristone, a potential cancer metastatic chemopreventive agent derived from mifepristone (RU486).Antiprogesterone RU 486--a drug for non-surgical abortion.The unique pharmacological characteristics of mifepristone (RU486): from terminating pregnancy to preventing cancer metastasis.Dexamethasone enhances oxidative stress-induced cell death in murine neural stem cells.Dose-response relationships of RU 486.Effects of Ketoconazole on the Pharmacokinetics of Mifepristone, a Competitive Glucocorticoid Receptor Antagonist, in Healthy Men.Role of glucocorticoid receptor-mediated mechanisms in cocaine memory enhancement.Thirty-day rat toxicity study reveals reversible liver toxicity of mifepristone (RU486) and metapristone.Evaluation of Evidence of Adrenal Insufficiency in Trials of Normocortisolemic Patients Treated With Mifepristone.
P2860
Q27010590-2E503F8D-63E7-452B-A813-8B123C44138CQ28067685-467374D3-CD3A-484D-AF8A-2D74D2192935Q28541028-157DF62B-CB62-49A2-857D-C2E6D98DFC2FQ30486738-5E3AD66E-E3A2-4E89-97DF-BCE1259794D7Q30499701-FCCA9E49-30D2-4D42-8EA1-CAC9A39A8020Q33371865-F0A7E374-4F3C-4AC1-9559-9E37C94884B6Q33752757-585216AE-DEF6-4DF7-B41C-E089AC42E8B8Q34740483-E4A47347-B022-4263-B0BA-2A228A0D00FEQ35441693-42C0D2C2-E221-4BEC-B89F-DA833020AD60Q35676274-0DC76F7B-77B1-4BFC-8CA9-2782FC1871DCQ36065578-7D3550B5-D1C2-4B68-9571-7D39E91DABD1Q36068813-772248F2-F600-4170-B60F-9A365D5F03D6Q36788416-4C61A6E7-B66C-40F6-B39E-DCDF76945FC0Q37144269-75C9DAA3-D74A-40B9-A9A4-09C04F3F018CQ37601043-F1E3C959-E0D7-48A1-8EF0-EFF3018EEDECQ37936433-E8BB9D28-CC29-4E7C-B9DB-271902A45246Q38192568-2E941039-F1EB-4E9C-A3FA-1FF31D7A8BE3Q39413557-5E4AB50F-671D-4BC4-B14B-986CE36DD722Q40851571-68BFC58A-E173-4688-B015-586DE0BA8E6BQ42696417-F73C6D82-310E-4EEE-8555-153AF2044467Q50582031-F853B939-610A-416D-8D57-DA252F62F6CFQ50927547-13F5573F-7C09-40F4-BB74-7EEBE69A053DQ53087307-34BB9186-99E4-4DF6-AC72-6EE726727850
P2860
Plasma concentrations and receptor binding of RU 486 and its metabolites in humans.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
1987年论文
@zh
1987年论文
@zh-cn
name
Plasma concentrations and receptor binding of RU 486 and its metabolites in humans.
@en
Plasma concentrations and receptor binding of RU 486 and its metabolites in humans.
@nl
type
label
Plasma concentrations and receptor binding of RU 486 and its metabolites in humans.
@en
Plasma concentrations and receptor binding of RU 486 and its metabolites in humans.
@nl
prefLabel
Plasma concentrations and receptor binding of RU 486 and its metabolites in humans.
@en
Plasma concentrations and receptor binding of RU 486 and its metabolites in humans.
@nl
P2093
P1476
Plasma concentrations and receptor binding of RU 486 and its metabolites in humans.
@en
P2093
Croxatto H
Heikinheimo O
Luukkainen T
Lähteenmäki P
P304
P356
10.1016/0022-4731(87)90083-5
P577
1987-02-01T00:00:00Z